Research programme: respiratory disorder therapeutics - Ipsen Bioinnovation

Drug Profile

Research programme: respiratory disorder therapeutics - Ipsen Bioinnovation

Alternative Names: SXN 100187; SXN 187

Latest Information Update: 17 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Syntaxin
  • Class Bacterial toxins; Botulinum toxins; Endopeptidases; Recombinant fusion proteins
  • Mechanism of Action Mucin inhibitors; SNARE protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 24 Jul 2013 Ipsen acquires Syntaxin
  • 24 Jul 2013 No development reported - Preclinical for Asthma in United Kingdom (Inhalation)
  • 24 Jul 2013 No development reported - Preclinical for Bronchitis in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top